72results about How to "Extended half-life" patented technology

The invention discloses a bovine I-type tau interferon-ferritin fusion protein as well as a mutant and application thereof. The bovine I-type tau interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that a conformation suitable for the ferritin nanocage to play functions is formed, and the expression level, the structural stability and the antiviral activity of the tau interferon are remarkably improved. The fusion protein is subjected to rational design mutation to obtain a single-site or multi-site mutant with significantly improved antiviral activity and stability. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles can be applied to preparation of a plurality of drugs for preventing or treating bovine viral infection, tumors and immune system diseases and immunologic adjuvants for vaccine compatibility.

Provided in the present invention are a class of compounds as represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, and an isotopic derivative thereof, or a pharmaceutically acceptable salt thereof. The compound has an SHP2 kinase inhibitory effect and can be used for treating and / or preventing diseases, disorders, and conditions mediated by SHP2 activity, such as tumors, cancers, cancer metastasis, cardiovascular diseases, immune disorders, visual disorders, etc.

The application discloses a functional sugar conversion enzyme and application. The functional sugar conversion enzyme enhances catalytic activity and thermal stability at 70 DEG C, and meanwhile, improves conversion efficiency of the functional sugar. The application has the operation advantages of green controllability, high product yield and low byproduct content, and has significant industrial application value.

The invention belongs to the technical field of green chemistry, and particularly relates to a method for modifying a flexible ring region of nitrile hydratase and application of the method. The specific method comprises the following steps: carrying out double mutation on nitrile hydratase sites alpha D38 and alpha I152, or carrying out double mutation on nitrile hydratase sites alpha E157 and beta G197, or carrying out quadruple mutation on the nitrile hydratase sites alpha D38, alpha I152, alpha E157 and beta G197, so as to construct the nitrile hydratase mutant with improved thermal stability. The thermal stability of the nitrile hydratase modified by mutation is greatly improved. The mutant nitrile hydratase can keep the conformation and activity for a longer time, the resistance to external thermal interference is enhanced, and the half-life period for catalyzing an adiponitrile reaction is remarkably prolonged, which is the inherent excellent attribute of the mutant nitrile hydratase as a catalyst, and the mutant nitrile hydratase has important reference significance for research on improvement of the thermal stability of the nitrile hydratase.

The present application relates to a preparation method for an antibody-drug conjugate and an application, and in particular, to a compound, or a tautomer, mesomer, racemate, enantiomer, and diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, a preparation method for the compound and related antibody-drug conjugates, and a use of the same in the preparation of drugs for the treating cancer.

This invention relates to the field of cosmetics, specifically to a composition containing copper peptides for repairing photothermal damage and its application. The composition comprises a complex polypeptide, galactosomal yeast fermentation product filtrate, and cyanobacterial extract; wherein the complex polypeptide includes copper peptides, yeast polypeptides, and hexapeptide-11. This invention, by combining specific complex polypeptides with galactosomal yeast fermentation product filtrate and cyanobacterial extract, increases the expression level of heat shock proteins, thereby achieving excellent efficacy in repairing photothermal damage. Furthermore, this composition is mild and non-irritating, and can be widely used in cosmetics.

The application discloses a pPAM long-circulating liposome, a preparation method and application thereof, and the long-circulating liposome takes a blank liposome as a carrier, internally carries a plasmid pPAM, and is decorated on the surface with a transferrin-penetratin complex Tf-Pen and an oxytocin receptor antibody OTR Ab； The plasmid pPAM carries a cDNA sequence of a peptide acylglycine alpha amidation monooxygenase PAM; and the blank liposome is composed of DSPC, PEG 2000 , cholesterol and lecithin. The application provides a new direction for development of endogenous polypeptide synthesis enzyme delivery technology and mental drugs, and improves the possibility of preparing new anti-anxiety and depression drugs, relieving mental stress and improving patient compliance.

The present application provides a series of substituted 1,2,4-triazole derivatives and their applications, and specifically provides a compound shown in formula (I) and a pharmaceutically acceptable salt thereof.

A multi-barrier coupled treatment process for organic complexed heavy metals in wastewater from battery cathode material production is disclosed, relating to the field of wastewater treatment. The method involves: 1. Adjusting the pH of the wastewater to 3.0-4.5; 2. Adding iron salt and peracetic acid to an oxidation reaction tank; 3. Achieving primary removal of heavy metals through neutralization and precipitation after oxidation; 4. Adjusting the pH of the wastewater back to 6.0-6.5; 5. Passing the wastewater sequentially through a primary adsorption unit and a secondary adsorption unit. This invention utilizes the low bond energy characteristics of PAA and the synergistic oxidation advantages of multiple free radicals to solve the bottleneck problems of incomplete complex breaking, large sludge production, and narrow pH application range in traditional methods. After treatment by this invention, the total nickel concentration in the effluent is less than 0.05 mg / L, and the total cobalt concentration is less than 0.02 mg / L, consistently exceeding the limits of the "Emission Standard of Pollutants for Battery Industry" (GB 30484-2013), demonstrating broad industrial application prospects.

The present application relates to a preparation method for and an application of an antibody conjugated drug, in particular to a compound, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, preparation methods of the compound and related antibody conjugated drug, and uses thereof in the preparation of drugs for treating cancers.

The invention discloses a 2-keto-inositol isomerase mutant and application thereof, and belongs to the technical field of gene engineering. The 2-keto-inositol isomerase mutant is obtained by performing at least one of the following mutations on an amino acid sequence as shown in SEQ ID NO.1: (1) mutating the 63rd amino acid from L to A; (2) the 155th amino acid is mutated from E to R; and (3) the 210th amino acid is mutated from G to R. After the wild type 2-keto-inositol isomerase is mutated, the obtained 2-keto-inositol isomerase mutant is higher in enzyme activity, better in heat resistance and longer in half-life period, and when the D-chiral inositol is prepared by combining with inositol dehydrogenase, the reaction conversion rate and the yield of the D-chiral inositol are improved.

A human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.

The present application relates to a fusion protein and use thereof. The fusion protein comprises a human GLP-1 polypeptide variant and an immunoglobulin Fc region, wherein an amino acid sequence of the human GLP-1 polypeptide variant comprises at least 2 amino acid mutations compared with an amino acid sequence set forth in SEQ ID NO: 2, and the at least 2 amino acid mutations are located at amino acid positions selected from the group consisting of W31, K26, and Y19. The present application also provides use of the fusion protein in treating a disease or a condition.

This invention relates to a fusion protein and its applications. Specifically, the invention provides a GCGR-IgG2 / Fc fusion protein, a polynucleotide encoding the fusion protein, a carrier containing the polynucleotide, a cell, and a composition thereof. It also relates to the use of the fusion protein, polynucleotide, carrier, cell, and composition in pharmaceuticals, and / or in the preparation of pharmaceuticals for the treatment or prevention of glucose metabolism-related diseases.

Provided are an anti-CLDN6 antibody or an antigen-binding fragment thereof; a nucleic acid molecule encoding same; an immunoconjugate, a bispecific molecule, a chimeric antigen receptor and a pharmaceutical composition containing same; and the use thereof for preventing and / or treating tumors.

This invention discloses a method for enhancing the waterlogging tolerance of sesame seedlings using melatonin and its application. The method utilizes alginate oligosaccharides, boric acid, melatonin, calcium chloride, polyalkylene oxide-modified heptamethyltrisiloxane, and deionized water as raw materials. Through a stepped temperature control and multi-channel synchronous assembly process, a cross-linked network is constructed to physically encapsulate melatonin, effectively shielding its photosensitive area to slow down UV photolysis. This method features low surface tension, allowing easy penetration into microcracks and stomata on plant leaves. After a small amount of water evaporates, an in-situ sol-gel phase transition is triggered, forming a hydrogel microfilm that adheres to the leaf tissue, resisting natural rainfall washout and achieving slow-release of melatonin. This invention effectively solves the problems of easy loss and photolysis of conventional exogenous agents, and the components synergistically activate basic plant immune and antioxidant pathways, systematically enhancing the waterlogging tolerance of sesame seedlings.

The invention discloses hydrogel capable of releasing growth factors after heat absorption and contraction and a preparation method of the hydrogel, and belongs to the field of biomedical materials. The hydrogel is of a three-layer composite structure, wherein the first layer is a sodium alginate-chitosan polyelectrolyte semi-interpenetrating network layer and serves as a compact protective layer; the second layer is a bacterial cellulose-sodium alginate high-toughness layer and is used as a bearing layer and a shrinkage driving layer; and the third layer is a basic fibroblast growth factor (bFGF)-loaded poly (butylene adipate / terephthalate) (PBAT) electrostatic spinning film layer and is used as a medicine storage cavern. According to the invention, the characteristic that the bacterial cellulose / sodium alginate layer can generate reversible heat absorption volume shrinkage at a specific temperature is used as a physical driving force to extrude and promote the bFGF in the third layer of PBAT fiber membrane to directionally release outwards.

The application discloses a bovine type I alpha interferon-ferritin fusion protein, a mutant thereof, and a preparation method and application thereof. The bovine type I alpha interferon is fused with a ferritin subunit, the self-assembly characteristics of the ferritin are utilized, the interferon molecules are highly repeated and orderly displayed on the surface of the ferritin nanocage, and the expression level, structural stability and antiviral activity of the interferon are significantly improved. The fusion protein is further subjected to rational design mutation at a unit point or multiple points, and a mutant with significantly improved antiviral activity and stability is obtained. The fusion protein or the mutant thereof is expressed by using a silkworm or insect cell eukaryotic expression system, the expression system is safe in operation, simple in procedure, low in cost, and extremely beneficial to large-scale industrial production, and the prepared fusion protein or mutant nanometer particle has application prospects in the preparation of medicines or reagents for preventing or treating bovine viral diseases.

The application discloses a kind of high thermal stability glutamine transaminase mutant and its method of expression in streptomyces, belong to enzyme engineering field.The high thermal stability glutamine transaminase mutant provided by the application can efficiently catalyze casein crosslinking at high temperature, realizes the heterologous efficient expression of glutamine transaminase.Rational mutation is carried out to key amino acid site of glutamine transaminase, and the mutant strain with significantly improved thermal stability is obtained.Among them, the optimal mutant strain FRAPD-TGm2A3 has a half-life of up to 537.91 min at 60 DEG C.The mutant can still efficiently catalyze the crosslinking reaction of casein at high temperature of 85 DEG C.The present application not only lays a solid research foundation for the modification of thermal stability of glutamine transaminase, but also provides a generalizable strategy framework for the rational modification of other thermostable enzymes, and has important industrial application value and academic reference significance.

The present invention relates to a method for stabilizing a fast decay component C3bBb complex of a bypass pathway of a complement system as well as a stabilized C3bBb complex and its use.

This disclosure pertains to the field of biomedicine, specifically relating to double-stranded oligonucleotides targeting the APP gene and their applications. Specifically, it provides double-stranded oligonucleotide agents or their salts, conjugates, or compositions for inhibiting amyloid precursor protein (APP) expression, wherein the double-stranded oligonucleotide agent comprises a sense strand and an antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:1-154 with a difference of no more than 3 nucleotides, and / or the sense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:155-308 with a difference of no more than 3 nucleotides. The double-stranded oligonucleotide agent or its salt for inhibiting APP expression disclosed in this application can significantly inhibit APP expression and can be used for the prevention and / or treatment of diseases or conditions mediated by the APP gene and / or associated with protein amyloidosis.

The invention discloses a stable solution preparation of medicinal GLP-1R antibody fusion protein, which comprises a therapeutically effective dose of GLP-1R antibody fusion protein, amino acid, a surfactant and a buffer system, the final concentration of the amino acid is 1-500mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution preparation is 5.0-8.0. The invention has the advantages of stable performance, long in-vivo half-life period and good treatment effect, and can be used for treating diabetes, obesity and related diseases thereof.

The invention relates to the technical field of biological medicines and functional nucleic acid molecules, and discloses pearl mussel source miRNA and application thereof, a biological preparation and application thereof. The pearl mussel source miRNA is miRNA derived from a pearl mussel pallium exosome, contains a sequence shown in SEQ ID NO: 1, and can be modified by phosphorylation, locked nucleic acid and the like to enhance the stability. The biological preparation containing the miRNA can be used for preparing a medicine for preventing and / or treating osteoporosis or functional food for promoting bone mineralization, and the bone mineral density and the bone microstructure are improved by promoting osteoblast proliferation, differentiation and mineralization. According to the invention, marine biological resources which are natural in source and high in safety are utilized, and new active ingredients and technical schemes are provided for prevention and treatment of osteoporosis.

The invention discloses a composition for promoting aquatic animal body surface tissue repair and a preparation method and application thereof.The composition is prepared from active ingredients, a biological adhesive and a protein stabilizer, the active ingredients are trachinotus ovatus recombinant IGF1 protein and trachinotus ovatus recombinant IGF2 protein, and the biological adhesive is a biological adhesive. The trachinotus ovatus recombinant IGF1 protein is a fusion protein containing an amino acid sequence as shown in SEQ ID NO: 2, and the N end of the trachinotus ovatus recombinant IGF1 protein is connected with an SUMO tag protein; the invention further discloses a preparation method of the composition for promoting aquatic animal body surface tissue repair and application of the composition in preparation of aquatic animal body surface tissue repair drugs. The composition has the advantages of fusion expression, stability, high efficiency, synergistic repair, low dosage, high efficiency, biological adhesion, long-acting slow release and the like.

This invention relates to the field of oilfield development technology, specifically to a high-temperature resistant oil displacement foaming agent, its preparation method, and its application. The method involves first preparing a main agent solution containing a high-temperature resistant additive and a main agent, then adding a foam stabilizer for compounding, and finally maturing to obtain the high-temperature resistant oil displacement foaming agent. The main agent includes alkyl aryl sulfonate derivatives, the high-temperature resistant additive is an acrylamide derivative, a styrene derivative, or an organophosphonate, and the foam stabilizer is modified guar gum. The compounding temperature is 120-150℃, the reaction pressure is 0.3-0.5 MPa, and the time is 4-6 hours. This method achieves synergistic effects among the main foaming agent, modified guar gum, and organophosphonate, forming a stable system. This high-temperature resistant oil displacement foaming agent possesses excellent thermal stability and interfacial activity; it exhibits both excellent high-temperature and salt resistance and efficient foaming, foam stabilizing, and oil displacement effects under ultra-high temperature, ultra-high salinity, and high calcium and magnesium ion environments.

Disclosed are ketone amide derivatives and applications thereof, and specifically disclosed are compounds of formula (IV) and pharmaceutically acceptable salts thereof.

The invention discloses a tanshinone IIA derivative as well as a preparation method and application thereof, and provides a set of systematic chemical synthesis route for overcoming the defects that tanshinone IIA is poor in water solubility and low in bioavailability and the antitumor activity needs to be improved. A series of novel derivatives with various structures and general formula structures and pharmaceutical salts thereof are prepared. The core of the technical scheme is that after a specific functional group is introduced into the derivative, the water solubility and the stability of the compound are remarkably improved, and the derivative particularly shows excellent anti-colorectal cancer activity, can effectively inhibit tumor cell proliferation and tumor growth in an animal model, and does not have obvious toxic or side effects. The invention also provides a pharmaceutical composition containing the derivative and application of the pharmaceutical composition in preparation of medicines for preventing, relieving or treating colorectal cancer, and provides an important candidate compound for developing a high-efficiency and low-toxicity novel anti-colorectal cancer medicine.

The invention provides a novel nano antibody-based recombinant long-acting human growth hormone fusion protein, nucleic acid, a pharmaceutical composition, application and the like. Existing long-acting means of PEGylation, Fc fusion and the like often cause reduction of activity, the human growth hormone is innovatively fused with an anti-albumin nano antibody with a specific sequence, and protein with larger molecules is formed through combination of the nano antibody and albumin antigen, so that the half-life period of the human growth hormone is prolonged, the activity of the human growth hormone is prolonged, and the human growth hormone can be used for preparing the anti-albumin nano antibody. In addition, the activity of the fusion protein provided by the invention is higher than that of a human growth hormone standard substance. The fusion protein and the like have wide industrial application prospects in the field of biological medicines.

This invention belongs to the field of medicinal chemistry, specifically relating to a mitochondrial-dequinoline chloride-hyaluronic acid compound, its preparation method, and its application. The rotenol-dequinoline chloride-hyaluronic acid compound has the following structural formula, where n is 2. Based on the anticancer activity of rotenone, this invention utilizes reduction, esterification, and two amide reactions to successfully link rotenol, dequinoline chloride, and hyaluronic acid via amide bonds. Subsequently, these components are successfully self-assembled into spherical nanoparticles using ultrasound, constructing a rotenol-dequinoline chloride-hyaluronic acid nanosystem for tumor therapy. After targeted delivery of these nanoparticles to tumor cells, both rotenol and dequinoline chloride synergistically act on the mitochondria, forming a dual-drug delivery system that generates a large amount of ROS, thereby inducing apoptosis and effectively inhibiting tumor growth and migration.

The present application provides siRNA delivery nanomaterials targeting M2 macrophages, which are mannosylated bovine serum albumin nanoparticles encapsulating siRNA interfering with KLK12. The mannose coating of the materials of the present application can provide targeting effect on M2 macrophages, and the siRNA released after endocytosis of the materials can silence the expression of KLK12 and its downstream MMPs genes, reduce the degradation of collagen fibers in lung tissues, thereby controlling the number and volume of pulmonary tuberculosis granulomas, preventing the occurrence of active tuberculosis, and providing a new option for the treatment of tuberculosis.